Following the 1 March 2026 Pharmaceutical Benefits System (PBS) updated listings for ipilimumab and nivolumab for the treatment of immunotherapy sensitive, advanced or metastatic cancers, eviQ has published its first broad indication tumour-agnostic immunotherapy protocol.
Recently, CNSA’s Education Manager, Dr Pammie Ellem, travelled to Darwin to represent the Cancer Nurses Society of Australia and support local cancer nurses through targeted professional development.
People with rare and less common cancers have been given new hope today, with the release of a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) that, if accepted, would make a potentially life-changing immunotherapy more affordable and available to those who need it.
The Australian Government has announced $1 million to fund projects that build stronger networks between cancer services in outer metropolitan, regional, rural, and remote communities, and larger metropolitan centres.
Rare Cancer Australia has launched the next learning module in their online Education Hub. The Thoracic Cancers Learning Module covers common cancers like lung cancer, as well as rare cancers like mesothelioma, thymic cancers and mediastinal germ cell tumours.
Cancer Institute NSW, in partnership with ACON, has launched the LGBTQ+ Inclusion Toolkit – a practical suite of resources to support more inclusive and equitable cancer outcomes across NSW.
